Mallinckrodt — Merger or Acquisition (December 2017)
18 slides from Mallinckrodt's merger presentation, Dec 26, 2017
Slide 1: Mallinckrodt Strategic Acquisition Sucampo Pharmaceuticals
Mallinckrodt Strategic Acquisition Sucampo Pharmaceuticals December 26, 2017 Exhibit 99.3
Slide 2: Forward-looking statements
Forward-looking statements Statements in this document that are not strictly historical, including statements regarding the proposed acquisition of Sucampo Pharmaceuticals, the expected timetable for completing the transaction, future financial condition and operating results, benefits and synergies
Slide 3: Forward-looking statements (continued)
Forward-looking statements (continued) Cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; The reimbursement practices of a small number of public or private insurers; Pricing pressure on certain of Mallinckrodt's products due to legal changes
Slide 4: Additional Information and Notice to Investors
Additional Information and Notice to Investors The tender offer for the outstanding Sucampo shares referenced in this document has not yet commenced. This document is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substi
Slide 5: Transaction highlights – acquisition of Sucampo, including AMITIZA and two development assets
Transaction highlights – acquisition of Sucampo, including AMITIZA® and two development assets Assuming expected Q1 2018 close, MNK expects accretion to 2018 adjusted diluted earnings per share of at least $0.30, and at least double that in 2019 Potential to monetize Priority Review Voucher in Pedia
Slide 6: Products marketed through commercial partners; acquired assets and status
1 Products are marketed through commercial partners, in various geographic markets. Indications approved/marketed may vary by market. Gloria is responsible for development, commercial, and regulatory activities in China for AMITIZA; 2 OIC includes patients with chronic pain related to prior cancer o
Slide 7: Acquisition builds on MNK's commitment to develop therapies for rare diseases
Acquisition builds on MNK’s commitment to develop therapies for rare diseases 1 Graft vs Host Disease 2 Deep Partial Thickness 3 Hepatorenal Syndrome 4 Amyotrophic Lateral Sclerosis 5 Full Thickness 6 Diabetic Foot Ulcers 7 Duchenne Muscular Dystrophy 8 Vascular Endothelial Growth Factor 9 Interleuk
Slide 8: Amitiza is an effective and differentiated treatment for constipation with a unique mode of action
Amitiza is an effective and differentiated treatment for constipation with a unique mode of action (MOA) Amitiza (lubiprostone) MOA1,2 Chloride channels in the intestinal tract help regulate fluid balance Amitiza works through highly selective activation of Chloride Channel-2 (CIC-2) channels in the
Slide 9: Broad indication, potential pediatric label extension, and unique MOA are key drivers for AMITIZA
Broad indication, potential for pediatric label extension, and unique MOA are key drivers for AMITIZA Key Brands in Constipation Market FDA-Approved Indications1 Mode of Action1 2016 IMS Net Sales (% Share)3 CIC OIC IBS-C Boxed Warning1 √ √ √ √ √ √ √ √ Chloride channel activator Guanylate cyclase-C
Slide 10: AMITIZA net sales will be received through commercial partnership agreements
AMITIZA net sales will be received through commercial partnership agreements Product Transfer Royalties Milestone Payments Other Contracted transfer price paid on a ‘per unit’ basis Milestone payments determined by commercial or regulatory milestones Receives R&D revenue from AMITIZA clinical develo
Slide 11: VTS-270 in Phase 3 for Niemann-Pick Type C
VTS-270 VTS-270: in Phase 3 for Niemann-Pick Type C (NPC), a hereditary, neurodegenerative disease Niemann-Pick Disease Overview Niemann-Pick disease primarily affects children/young adults Genetic mutations affect cellular metabolism and lead to accumulation of lipids in spleen, liver, lungs, bone
Slide 12: NPC Progression, Prognosis, Prevalence
NPC Progression, Prognosis, Prevalence NPC is rare, difficult-to-diagnose, often fatal condition primarily affecting children, young adults 1 National Niemann Pick Disease Foundation ; 2 Patterson M. Niemann-Pick Disease Type C. GeneReviews. July 2013; 3 Garver WS et al. Am J Med Genet A. 143A(11):
Slide 13: VTS-270 has potential to be first FDA-approved, disease-modifying agent targeting NPC
VTS-270 has potential to be first FDA-approved, disease- modifying agent targeting NPC via direct MOA Current Options for NPC1-5 Regulatory Approval6,7 Target1-5 Antiepileptics Not approved for NPC Seizures Tricyclic antidepressants Cataplexy CNS8 stimulants Anticholinergics Dystonia and Tremor Trih
Slide 14: VTS-270 Phase 1/2 trial results show clinical improvements in patients with NPC
VTS-270 Phase 1/2 trial results show promising clinical improvements in patients with NPC 14 participants treated monthly showed slower increase in total NNSS1 compared with control cohort2 Rate of disease progression slowed for ambulation, cognition, and speech (major portions of NNSS) in participa
Slide 15: CPP-1X/sulindac in Phase 3 for FAP
CPP-1X/sulindac in Phase 3 for FAP, an often inherited genetic condition involving potentially malignant polyps Familial Adenomatous Polyposis (FAP) Overview FAP caused by genetic mutation leading to uncontrolled growth of hundreds to thousands of polyps in lower digestive tract1 Most patients (~70%
Slide 16: CPP-1X/sulindac aims to provide surgical alternative in FAP patients
CPP-1X/sulindac aims to provide surgical alternative in FAP patients, reduce polyp formation Current interventions for FAP are limited to endoscopies and gastrointestinal tract surgeries1 1 Mount Sinai Zane Cohen Centre; 2 Proof of Concept 3 Meyskens FL, et al. Cancer Prev Res. 2008;1:32-38; 4 Clini
Slide 17: Acquisition of Sucampo advances efforts to address high unmet patient need
Mallinckrodt’s acquisition of Sucampo advances our efforts to address high unmet patient need Development, regulatory expertise to gain product approvals Growing launch capabilities to optimize new product values Strong market access and HEOR1 infrastructure to maximize rare disease opportunities 1
Slide 18: Sucampo aligns with MNK strategic vision
Sucampo aligns with MNK strategic vision: Innovation-driven specialty pharmaceutical growth company focused on improving outcomes for patients with severe and critical conditions Development assets serve NPC and FAP patients with limited treatment options Deepens Mallinckrodt’s focus on rare disease